Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.

Cellectis Trading Down 2.6 %

Shares of CLLS stock opened at $1.90 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. Cellectis has a 1-year low of $0.96 and a 1-year high of $3.77. The firm has a market capitalization of $105.61 million, a PE ratio of -1.47 and a beta of 3.09. The business’s fifty day moving average price is $2.18 and its 200 day moving average price is $2.36.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.05. The firm had revenue of $9.50 million during the quarter, compared to the consensus estimate of $6.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. As a group, sell-side analysts forecast that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Baillie Gifford & Co. boosted its stake in shares of Cellectis by 1.3% during the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after acquiring an additional 10,605 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the period. XTX Topco Ltd purchased a new position in Cellectis during the second quarter worth about $29,000. First Affirmative Financial Network acquired a new stake in Cellectis in the 3rd quarter worth about $45,000. Finally, Long Focus Capital Management LLC increased its stake in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.